Targeting the Tumor Microenvironment for Pancreatic Ductal Adenocarcinoma Therapy

Yi-Fan Zhang; Shu-Heng Jiang; Li-Peng Hu; Pei-Qi Huang; Xu Wang; Jun Li; Xue-Li Zhang; Hui-Zhen Nie; Zhi-Gang Zhang

Disclosures

Chin Clin Oncol. 2019;8(2) 

In This Article

Discussion

Due to its complex microenvironment, PDAC suppresses the immune system and resists radiotherapy and chemotherapy, causing cognitive difficulty in PDAC patients. The soluble proteins and cells that surround the tumor cells stop drugs and immunocytes from reaching the cancer cells, which results in difficulties for therapy and a low overall 5-year survival rate. Breaking this obstacle has become the first step to treating pancreatic cancer, but recent clinical research has not found an effective way to approach and kill pancreatic cancer cells. The studies that targeted CAFs and PD-1 immune inhibitors have shown the effort applied in advancing pancreatic cancer therapy, but it is not enough. More factors and mechanisms need to be found to support the basic knowledge behind clinical work, and more drug and therapy methods need to be applied to identify basic scientific problems.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....